Organisation/Company: Università degli studi di MessinaResearch Field: Medical sciences, Biological sciences, Pharmacological sciencesResearcher Profile: Recognised Researcher (R2), Leading Researcher (R4), First Stage Researcher (R1), Established Researcher (R3)Country: ItalyApplication Deadline: 14 Jan 2025 - 12:00 (UTC)Type of Contract: To be definedJob Status: Not ApplicableIs the job funded through the EU Research Framework Programme?
Not funded by a EU programmeIs the Job related to staff position within a Research Infrastructure?
NoOffer DescriptionThe project focuses on the issue of the immunogenicity associated with RNA therapeutics, one of the main obstacles to their development.
The project aims to identify the key immune sensors involved in the reactogenicity of RNA drugs, analyzing how these sensors interact with prototype RNA therapy molecules of different immunogenicity.
Using a large panel of genetically modified mice, lacking key molecules of the innate immune system, the immunological mechanisms underlying the responses to these drugs will be studied.
The project includes a series of activities exploring the role of specific immune receptors and sensors, such as MAVS, ZBP1, Myd88, RI, SING, and NRP3, in mediating the immune response to RNA drugs.
The final goal is to improve the safety and efficacy of RNA therapeutics.Minimum RequirementsMaster's/specialist/old system degree relating to the relevant scientific disciplinary area obtained in Italy or the equivalent qualification obtained abroad.Degree Course in Medicine and Surgery (LM41)Degree Course in Medical, Veterinary and Pharmaceutical Biotechnology (LM9)Bachelor's Degree in Chemical, Biological, Pharmaceutical and Environmental Sciences (LM6)DOCTORATE on subjects related to the topics of the research grantEligibility of fellows: country/ies of residence: EUROPEEligibility of fellows: nationality/ies: EUROPESelection ProcessThe selection process will focus on RNA-based therapeutics, molecular mechanisms of innate immunity, and immune sensors in adverse drug reactions related to RNA-based therapeutics.
#J-18808-Ljbffr